9 completed. 9 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 9 | Completed 9 |
| Phase 2 | 1 | Completed 1 |
Follow Nac: new trials by email Literature Review of Nac trials Research Report on Nac
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients N-acetyl cysteine, Metfomin - Polycystic Ovary Syndrome | Phase 3 | Completed | Cairo University | 102 | 2025-03-01 | 2026-10-21 |
| NAC vs Placebo on Opioid Use for Hysterectomy IV N-acetylcysteine, IV Placebo - Hysterectomy | Phase 3 | Completed | Medical University of South Carolina | 240 | 2023-11-30 | 2026-10-09 |
| Prospective Treatment Efficacy in IPF Using Genotype for Nac Selection (PRECISIONS) Trial N-acetyl cysteine, Placebo - Idiopathic Pulmonary Fibrosis | Phase 3 | Completed | Fernando J Martinez | 202 | 2020-12-17 | 2026-03-20 |
| A Safety and Efficacy Study of NAC in Patients With TA-TMA N-Acetylcysteine, Placebo Oral Tablet - Thrombotic Microangiopathies, Hematologic Diseases | Phase 3 | Completed | The First Affiliated Hospital of Soochow University | 170 | 2017-11-01 | 2022-02-14 |
| NAC Effect on Hox Genes Expressions in RIF N-acetyl cysteine, Placebos - Female Infertility | Phase 3 | Completed | Royan Institute | 40 | 2015-02-01 | 2019-03-05 |
| Achieving Cannabis Cessation-Evaluating N-Acetylcysteine Treatment N-Acetylcysteine, Placebo - Cannabis Dependence | Phase 3 | Completed | Medical University of South Carolina | 302 | 2014-01-01 | 2018-05-24 |
| Prevention of Serious Adverse Events Following Angiography IV isotonic saline, IV isotonic bicarbonate, N-acetylcysteine - Acute Renal Failure, Kidney Disease | Phase 3 | Completed | VA Office of Research and Development | 5177 | 2013-10-07 | 2025-11-05 |
| Use of N-Acetylcysteine (NAC) in Fingernail Biting N-Acetylcysteine (NAC), Placebo - Onychophagia | Phase 3 | Completed | Kevin Gray, MD | 23 | 2013-10-01 | 2018-10-03 |
| Protective Effect of N-acetylcysteine Against From Ototoxicity N-acetylcysteine - Hearing Loss, Extreme | Phase 2 / Phase 3 | Completed | TC Erciyes University | 60 | 2010-06-01 | 2011-11-16 |
Acute Kidney Injury (1) · Anxiety Disorders (1) · Attention Deficit Disorder with Hyperactivity (1) · Coronary Artery Disease (1) · Deafness (1) · Depression (1) · Hematologic Diseases (1) · Idiopathic Pulmonary Fibrosis (1) · Infertility, Female (1) · Kidney Diseases (1) · Marijuana Abuse (1) · Nail Biting (1) · Ototoxicity (1) · Peritonitis (1) · Polycystic Ovary Syndrome (1)
Medical University of South Carolina (2) · Cairo University (1) · Fernando J Martinez (1) · Kevin Gray, MD (1) · Royan Institute (1) · TC Erciyes University (1) · The First Affiliated Hospital of Soochow University (1) · VA Office of Research and Development (1)
United States (5) · Australia (1) · China (1) · Egypt (1) · Malaysia (1) · New Zealand (1) · Turkey (Türkiye) (1)
Kevin M Gray, MD (2) · Amr Z Abdelhamid, PhD (1) · Ashraf Moini, MD (1) · Cathie Spino, ScD (1) · Depei Wu, MD. PhD. (1) · Eglal A Mostafa Bassiouny, PhD (1) · Fernando J Martinez, MD (1) · Imre Noth, MD (1) · Ismail Kocyigit, MD (1) · Kevin Flaherty, MS, MD (1) · Maryam Shahhoseini, PhD (1) · Parvaneh Afsharian, PhD (1) · Samar F Farid, PhD (1) · Seyed Mehdi Kalantar, PhD (1) · Steven D. Weisbord, MD MSc (1)
PMID 25073872, PMID 28623823, PMID 28847455, PMID 29130810, PMID 31712969, PMID 34197135, PMID 35084903, PMID 36514019
U10DA013045 (1), U10DA013727 (1), U10DA013732 (1), U10DA015815 (1), U10DA015831 (1), U10DA020024 (1), U24HL145265 (1), UG1DA013727 (1)